Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005029 · ClinicalTrials.gov registry record · Phase 2
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00005029: Clinical Trial Phase 2 study, sponsored by Gynecologic Oncology Group.
NCT00005029 is a Phase 2 study that was terminated before completion, run by Gynecologic Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005029, a Phase 2 study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of topotecan in treating patients who have recurrent ovarian epithelial or primary peritoneal cancer.
Interventions
- DRUG topotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-02 |
| Phase | Phase 2 |
Why NCT00005029 stopped before completion
NCT00005029 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which topotecan hydrochloride is the first listed.
NCT00005029 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005029 about?
NCT00005029 is a clinical study titled "Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of topotecan in treating patients who have recurrent ovarian epithelial or primary peritoneal cancer.
What is the current status of trial NCT00005029?
This trial is currently terminated. It is a Phase 2 study. The study started on 2000-02.
What interventions are being tested in trial NCT00005029?
The interventions under investigation include: topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00005029?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia